Business Wire

PUMA Partners With adam&eveDDB to Bring New Global Brand Strategy to Life

5.12.2024 11:00:00 CET | Business Wire | Press release

Share

New Brand Campaign in 2025 Will Be Focused on the Emotional Aspects of Sport

Global sports company PUMA, in partnership with creative agency adam&eveDDB, continues its journey of elevating the brand with a new brand marketing strategy in 2025, establishing PUMA as a leading sports performance brand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205156959/en/

Global sports company PUMA, in partnership with creative agency adam&eveDDB, continues its journey of elevating the brand with a new brand marketing strategy in 2025, establishing PUMA as a leading sports performance brand. (Photo: Business Wire)

Founded in 1948 by Rudolf Dassler, PUMA was born from a vision to craft footwear that empowers athletes to embody the agility, speed, and spirit of a puma itself. For 75 years, PUMA has been at the forefront of innovation, partnering with the world’s fastest athletes, iconic clubs, and legendary federations to push the boundaries of performance. Over the last few years sports culture has moved from a narrow focus on winning – sweat, grit and struggle against the odds – to a more authentic and human space.

With the recent appointment of Julie Legrand as Senior Director of Global Brand Strategy and Communications, PUMA aims to shape the next chapter of its unique journey. Legrand, who was previously the Global Brand Director of H&M and has over a decade of experience at Procter & Gamble, dedicated 2024 to refining PUMA’s brand DNA and architecture, crafting a distinct and bold position in the market. “Part of my mission when joining the PUMA team early this year, was to oversee and further elevate the PUMA brand in the minds of consumers. I am delighted to be working with adam&eveDDB to delve into our DNA and to develop a brand campaign for 2025 that brings to life our new global brand strategy. With their emotionally charged creativity we can build deeper, more meaningful connections with our consumer.

For Richard Teyssier, PUMA Vice President Brand & Marketing, “PUMA is the home to some the best athletes, teams and ambassadors in the world and we have a clear ambition to position PUMA as a leading sport performance brand. We aim to be at the forefront of innovation and trends, not only on our products but especially when it comes to the brand and marketing. With adam&eveDDB, we found a partner capable of helping us build an emotional connection with our consumers, while unifying the PUMA brand under a single global strategy across our extensive sports portfolio.

This year, PUMA partnered with adam&eveDDB, a creative company committed to placing emotion at the core of every interaction between businesses and consumers. adam&eveDDB’s strategy will elevate the brand by bringing PUMA’s impressive credentials to the fore, establishing it as the leading sports performance brand. “Communicating all that PUMA has to offer is a gift. Our teams in London and Berlin are immersed in all the feelings that get people moving; we can’t wait to tell the brand's unique story which has been so brilliantly distilled by Julie and the team,” said Miranda Hipwell, CEO at adam&eveDDB.

adam&eveDDB’s first global brand campaign for PUMA will launch in spring 2025. The PUMA account will be led by teams from adam&eveDDB’s London and Berlin offices.

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

adam&eveDDB

adam&eveDDB is a creative agency based in London, Berlin, New York, and San Francisco. They believe in the power of creativity to unlock business advantages for brands. An agency that feels welcoming and responsible. We work with a range of clients including Amazon, CALM, PlayStation, Eurostar, Marmite, Lloyds Bank, Savills, Volkswagen and MARS.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205156959/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye